Lantern Pharma Inc.
LTRNHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeLantern Pharma Inc. focuses on the discovery and development of oncology drug in India. At a $24.4M market cap, Lantern Pharma Inc. ranks as a micro-cap company within healthcare. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.
Market Cap
$24.4M
Beta
2.30
P/E (TTM)
—
P/E (Fwd)
-0.94
EPS (TTM)
$-1.63
EPS (Fwd)
$-2.02
ROE
-400.9%
ROA
-74.3%
Cash
$7.4M
Total Debt
$39,715
Free CF
-$8.2M
52W Change
-53.0%
Annual Financials
Cash vs Debt
Where LTRN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, LTRN finished 30.32% below its 150-day moving average ($2.77) and 34.35% below its 200-day moving average ($2.94). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LTRN overbought or oversold?
At the September 3, 2026 close, LTRN's RSI(14) was 14.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $7.4M in cash and $40K in debt, LTRN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$8.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -400.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Lantern Pharma Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, LTRN has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Lantern Pharma Inc. and its sector.